

Pediatric Hyperlipidemia

R. Peter Vande Kappelle, MD

Pediatric Cardiologist

Akron Children's Hospital



Objectives

1. Describe pediatric hyperlipidemia
2. Recognize abnormal pediatric lipid levels
3. Outline the treatment for pediatric hyperlipidemia



1. Describe Pediatric Hyperlipidemia

- Lipid is a non soluble material in liquid
 - Includes:
 - Cholesterol
 - Triglyceride
 - Phospholipids
- Lipids form cell membranes, produce bile acids, and are used in hormone synthesis
- Exogenous – taken in with food
- Endogenous – synthesized within the body




1. Describe Pediatric Hyperlipidemia

- Exogenous – Intestinal absorption of dietary cholesterol and fatty acids
 - Saturated fats (Meats, dairy especially whole milk products, coconut oil, palm oil, cocoa butter)
 - Trans fats (Historically crackers, baked goods, french fries, donuts)
 - Cholesterol (Egg yolks, organ meats)
- Endogenous – Synthesis in the liver

1. Describe Pediatric Hyperlipidemia

- Lipids are carried in the blood stream by complexes called lipoproteins
- Lipoproteins Classes:
 - Chylomicrons – from the intestines
 - Very low density lipoprotein
 - Intermediate density lipoprotein
 - Low density lipoprotein – serum
 - High density lipoprotein – reverse transport



1. Describe Pediatric Hyperlipidemia

- Normal pediatric lipid levels
 - Total cholesterol <170
 - LDL cholesterol <110
 - HDL cholesterol >45
 - Triglycerides <90
 - Non-HDL cholesterol: <145
- Pediatric hyperlipidemia is an increase in triglycerides and/or LDL cholesterol

1. Describe Pediatric Hyperlipidemia


- Abnormal pediatric lipid levels
 - Total cholesterol >200
 - LDL cholesterol >130
 - HDL cholesterol <40
 - Triglycerides >130

1. Describe Pediatric Hyperlipidemia

- Primary dyslipidemia
 - Familial hypercholesterolemia
 - American diet
- Secondary dyslipidemia
 - Diabetes mellitus/Metabolic syndrome
 - Biliary atresia/cholestasis/Hepatitis
 - Nephrotic syndrome/renal failure
 - Hypothyroidism
 - Kawasaki disease/rheumatoid arthritis/SLE
 - Medications (Steroids, OCP's)

1. Describe Pediatric Hyperlipidemia

- Heterozygous familial hypercholesterolemia
 - 1 in 250 are affected
- Homozygous familial hypercholesterolemia
 - 1 in 1 million are affected



1. Describe Pediatric Hyperlipidemia

- As weight increases, so does the likelihood of an abnormal cholesterol panel
 - Normal weight: 14% with lipid panel abnormality
 - Overweight: 22% lipid panel abnormality
 - Obese patients: 42% lipid panel abnormality

2. Recognize Pediatric Hyperlipidemia

- Serum lipid panel
 - Total Cholesterol= LDL + VLDL +HDL
 - LDL is calculated (Valid only if TG<400)
 - Often underestimates IDL component
 - VLDL = TG/5
 - Triglycerides
 - LDL
 - HDL
 - Non HDL cholesterol= TC – HDL

2. Recognize Pediatric Hyperlipidemia

- Previous recommendations
 - Check Total cholesterol or fasting lipid profile on any patient after the age of 2 if:
 - Parental total cholesterol >240
 - Family history of PCAD in parents or grandparents(<55 in males or <65 in females)
 - Unknown family history
 - Patient with obesity, hypertension, or diabetes

2. Recognize Pediatric Hyperlipidemia

- CARDIAC program trialed universal screening of 20,266 fifth grade students in West Virginia
 - 71.4% of patients that would have met the AAP screening criteria:
 - 8.3% had LDL >130mg/dL
 - 1.2% had LDL >160
 - 28.6% of pts wouldn't have been screened
 - 9.5% had LDL >130mg/dL
 - 1.7% had LDL >160

2. Recognize Pediatric Hyperlipidemia

- In 2011, the National Lipid Association recommended universal screening for all children between the ages of 9-11 years
 - Fasting lipid panel
 - Or non-fasting non-HDL cholesterol
- Earlier lipid screening can still be performed starting after age 2 for high risk patients


2. Recognize Pediatric Hyperlipidemia

- Physical examination
 - Tendon Xanthoma
 - Accumulation of lipids in cutaneous foam cells
 - Associated with marked elevation of cholesterol



2. Recognize Pediatric Hyperlipidemia

- Corneal Arcus - a lipid-rich corneal deposit that does not affect the patient's vision. It begins at the top and bottom of the cornea and spreads to form a complete ring




3. Treatment of Pediatric Hyperlipidemia

- First line therapy
 - Diet
 - Can decrease triglycerides and LDL cholesterol
 - Exercise
 - Daily exercise is the best way to increase low HDL levels

3. Treatment of Pediatric Hyperlipidemia

- Diet
 - Reduce saturated fats (red meat, dairy products) and trans fats (baked goods, desserts, crackers)
 - Goal saturated fat <10% of daily caloric intake
 - Limit daily cholesterol intake <200mg
 - Use only nonfat dairy products
 - Increase daily grams of fiber to (age + 5), up to 25 grams maximum

3. Treatment of Pediatric Hyperlipidemia




3. Treatment of Pediatric Hyperlipidemia

- 5-2-1-0 Obesity prevention plan
 - 5 Fruits/Vegetables daily
 - 2 Or less hours of screen time daily
 - 1 Hour of moderate physical activity daily
 - 0 Soda, juice, sport drinks daily

3. Treatment of Pediatric Hyperlipidemia

- Exercise
 - AAP recommendations are for all pediatric patients to get a minimum of 60 minutes of sweat producing exercise every single day!



3. Treatment of Pediatric Hyperlipidemia

- Second Line Therapy
 - Plant Stanols/Sterols
 - Omega 3 fatty acids
 - Prescription pharmacotherapy

3. Treatment of Pediatric Hyperlipidemia

- Plant Stanols/Sterols
 - Decrease absorption of cholesterol in GI tract
 - Often recommended as 2 - 4 grams per day
 - Shown to lower LDL cholesterol by 5-10%
 - Can be found in certain grocery store products:
 - Added to margarine
 - Added to orange juice

3. Treatment of Pediatric Hyperlipidemia

- Omega 3 fatty acids
 - Essential unsaturated fatty acids
 - Found in fish oils as well as flaxseed oil
 - Usual dose 2-4 grams daily
 - Works best to reduce elevated triglycerides

3. Treatment of Pediatric Hyperlipidemia

- Prescription pharmacotherapy (statins, bile acid resins, fibrates)
 - If LDL cholesterol >190 with no other risk factors
 - If LDL >160 with FHx PCAD, or 1 high risk factor or two moderate risk factors
 - If LDL >130 with 2 high risk factors or 1 high risk and two moderate risk factors

3. Treatment of Pediatric Hyperlipidemia

High-level risk factors:

Hypertension that requires drug therapy (BP \geq 99th percentile + 5 mmHg)

Current cigarette smoker

Obesity with BMI \geq 97th percentile

- Presence of a high risk condition: Diabetes (type 1 or type 2)
- Chronic kidney disease/end-stage renal disease/post-renal transplant
- Post-orthotopic heart transplant
- Kawasaki disease with current aneurysms

Moderate-level risk factors:

Hypertension (defined as systolic and/or diastolic BP \geq 95th percentile measured on three or more separate occasions) that does not require drug therapy

- Obesity: For children age 2 to 11 years: BMI \geq 95th to <97th percentile
- For adolescents \geq 12 years: BMI \geq 85th to <97th percentile

HDL cholesterol <40 mg/dL

- Presence of a moderate risk condition: Kawasaki disease with regressed coronary aneurysms
- Chronic inflammatory disease (eg, systemic lupus erythematosus, juvenile idiopathic arthritis)
- HIV infection
- Nephrotic syndrome
- Adolescent depressive and bipolar disorders[¶]

3. Treatment of Pediatric Hyperlipidemia

- Statins (Atorvastatin)
 - 3-Hydroxy-3-methyl-glutaryl Coenzyme A reductase inhibitors
 - Upregulate LDL receptors which clear LDL from the circulation
 - 20-50% reduction in LDL cholesterol
 - SE: Can elevate liver enzymes, cause rhabdomyolysis
Possibly teratogenic to fetus



3. Treatment of Pediatric Hyperlipidemia

- Bile acid binding resins (Cholestyramine)
 - Bind the cholesterol containing bile acids in the GI tract and prevent reuptake in the enterohepatic circulation
 - Can lower cholesterol 10-20%
 - SE: GI symptoms



3. Treatment of Pediatric Hyperlipidemia

- Ezetemibe
 - Inhibits cholesterol absorption from intestine
 - Blocks the cholesterol transporting NPC1L1 protein
 - The liver subsequently increases absorption of cholesterol from the blood stream and reduces LDL cholesterol 15%
 - Often used in combination with statin or in statin intolerant patients
 - Potential side effects can be diarrhea, fatigue, jaundice, rhabdomyolysis

3. Treatment of Pediatric Hyperlipidemia

- Fibrates (Gemfibrozil)
 - Inhibit synthesis of VLDL apolipoprotein B
 - Decreased hepatic extraction of free fatty acids, thus decreasing hepatic triglyceride production
 - SE: rhabdomyolysis, especially when used in combination with a statin



3. Treatment of Pediatric Hyperlipidemia

- PCSK9 Inhibitor (Evolocumab)
 - Proprotein convertase subtilisin/kexin type 9 inhibitor blocks the breakdown of LDL receptors
 - More LDL receptors allows for more removal of LDL from the bloodstream
 - Reduced LDL by 44% in one study of pediatric patients age 10-17 years old
 - Subcutaneous injection monthly
 - SE: Fatigue, muscle pain


3. Treatment of Pediatric Hyperlipidemia

- Monoclonal antibody inhibitor of ANGPTL3
 - IV monthly injectable (Evinacumab)
 - Doesn't require LDL receptors to function
 - Use in children ages 5 and older for homozygous familial hypercholesterolemia
 - Had significant reduction of 40% LDL by 2 weeks and sustained reduction in LDL to approximately 48% over 24 week period

3. Treatment of Pediatric Hyperlipidemia

- Children ages 8-18 started on statin therapy had less carotid intimal media thickness than those not treated at reevaluation at 4.5 years
- Teenagers started on statins had no cardiovascular events by age 30, when their affected parent had 7% CHD event rate by age 30
- Adults taking lipid lowering drugs for 13 years had protection against progression of carotid intima media thickness

3. Treatment of Pediatric Hyperlipidemia



LDL = low-density lipoprotein
LDL-C = LDL cholesterol
HDL-C = high-density lipoprotein cholesterol
CHD = coronary heart disease
FH = familial hypercholesterolaemia

Summary

- Pediatric hyperlipidemia is a common disorder
- Patients are asymptomatic and the only way to diagnose is with lipid screening
- Recommendations are to screen every child
 - Typically best age is 9-11 years old
 - Can screen after age 2 for high risk patients
- Pharmacotherapy can be effective and safe in pediatric patients

Thank You!

